Keywords: possible, extension, protection, daypro, searle, oxaprozin, non-steroidal
POSSIBLE EXTENSION ON PROTECTION FOR DAYPRO
Article | 06 December 1993
- Searle's Daypro (oxaprozin) non-steroidal anti-inflammatory may gain an extra two years of market exclusivity under new legislation recently introduced in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
